As ivacaftor was shown to improve CFTR function, but also reduce levels of circulating inflammation (56), the current study has not established whether the observed differences in CF phagosomes is due to CFTR dysfunction or the underlying inflammatory burden, and this is a limitation of the study. The gene discussed is CFTR; the disease is cystic fibrosis.